Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Low-Income Assistance Deals Reached With Most Medicare Rx Card Sponsors

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck has reached agreements with 34 of 36 card sponsors to offer drugs free of charge once $600 transitional assistance is exhausted.

You may also be interested in...



Abbott Expands Medicare Assistance Program To Include $5 Synthroid Scripts

The program will be available to low-income Medicare drug card members who exhaust their $600 annual credit. Abbott’s program already offers Humira free of charge and will be expanded to include chronic condition drugs for $12 per monthly script and Synthroid for $5 per month.

Abbott Expands Medicare Assistance Program To Include $5 Synthroid Scripts

The program will be available to low-income Medicare drug card members who exhaust their $600 annual credit. Abbott’s program already offers Humira free of charge and will be expanded to include chronic condition drugs for $12 per monthly script and Synthroid for $5 per month.

J&J Offers Free Drugs To Low-Income Medicare Discount Card Holders

Free drugs will be available to beneficiaries who exhaust the government’s $600 drug credit. J&J will also offer “competitive discounts” to seniors who do not qualify for the low-income program.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel